Oppenheimer has initiated coverage on Larimar Therapeutics, emphasizing its lead program Nomlabofusp as a transformative therapy for Friedreich's ataxia. With a price target of $26, the company plans ...

In June, Teva Pharmaceuticals Inc. TEVA reportedly sued Corcept Therapeutics ... Price Action: CORT stock is up 5.19% at $46.21 at the last check on Monday.

Corcept could be significantly undervalued based on long term potential growth and science-based innovation. Find out why ...

Briquilimab was well tolerated in the study. No SAEs or AEs grade 3 were reported. Furthermore, there were no reported AEs related to hair or skin color changes, hypersensitivity, or anemia. Mild ...

Testing volume at Modern Canna in Lakeland could as much as triple if Floridians vote to legalize the recreational ...

Shares of Celldex Therapeutics CLDX lost 12.1% on Wednesday due to unsatisfactory 52-week safety data from a mid-stage study ...

In total, investors put $40.5 billion into startups across all stages in Q3. That’s a decline of 10% from the prior quarter ...

Prohibiting medical use of the substance colloquially known as “molly” and reinforcing its Schedule I classification, the early-August decision rejecting Lykos Therapeutics’ application for ...

Perspective Therapeutics has done well to advance several radiotherapeutics to treat various types of cancers. Again, I think it was important to bring up VMT-01 for the targeting of patients with ...

The optimism for therapeutics is so much greater than even two or three ... Disinhibited behavior—doing things that are a bit off-color or out of character for that individual," Dr. Boeve explains.

Find out what Sophie Hahn, Kate Harrison and Adena Ishii have to say about public safety, housing and their big ideas for ...

Despite a challenging biotech market, Lineage Cell Therapeutics Inc (LCTX) strengthens partnerships and maintains a strong ...